GW Pharmaceuticals to Present at Two Upcoming Investor Conferences
September 21 2015 - 8:46PM
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company"
or "the Group"), a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform, announced that Justin
Gover, GW's Chief Executive Officer, is scheduled to present at the
Morgan Stanley Global Healthcare Conference to be held at the Grand
Hyatt New York on 16 September, 2015 at 4:15 p.m. EDT and Adam
George, GW's Chief Financial Officer is scheduled to present at the
Bank of America Merrill Lynch Global Healthcare Conference 2015 at
the Bank of America Merrill Lynch office in London, England on 17
September, 2015 at 3:25 p.m. BST.
A live audio webcast of the presentations will be available
through GW's corporate website in the investor relations section
from the investor's calendar of events page at
www.gwpharm.com. A replay will be available soon
after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex®, which is approved for the
treatment of spasticity due to multiple sclerosis in 27 countries
outside the United States. GW is advancing an orphan drug program
in the field of childhood epilepsy with a focus on Epidiolex® (CBD
or cannabidiol), which is in Phase 3 clinical development for the
treatment of Dravet syndrome and Lennox-Gastaut syndrome and which
is also expected to enter Phase 3 clinical trials in the treatment
of Tuberous Sclerosis Complex. GW has a deep pipeline of additional
cannabinoid product candidates which includes Sativex in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer, as well as compounds in Phase 1 and 2 trials
for glioma, type 2 diabetes, and schizophrenia. For further
information, please visit www.gwpharm.com.
CONTACT: Enquiries:
GW Pharmaceuticals plc
(Today) +44 20 3727 1000
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK)
+ 44 20 3727 1000
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024